Quadrature Capital’s Pliant Therapeutics PLRX Stock Holding History

Quadrature Capital’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.9K	Sell	33,280 -17,701	-35%	-$21.5K	﹤0.01%	1522
2026 Q1	$64.2K	Sell	50,981 -46,910	-48%	-$59.2K	﹤0.01%	1270
2025 Q4	$119K	Buy	97,891 +60,296	+160%	+$90.6K	﹤0.01%	1071
2025 Q3	$55.5K	Sell	37,595 -23,626	-39%	-$36K	﹤0.01%	948
2025 Q2	$71.3K	Sell	61,221 -6,304	-9%	-$8.91K	﹤0.01%	918
2025 Q1	$91.5K	Buy	+67,525	New	+$410K	﹤0.01%	938

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Quadrature Capital's PLRX Position: Q2 2026 in Review

Quadrature Capital reduced its Pliant Therapeutics (PLRX) stake by 35% in Q2 2026, selling an estimated $21.5K and leaving 33,280 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1522.

Quadrature Capital first reported a position in PLRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $119K in Q4 2025. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Quadrature Capital held 33,280 shares of Pliant Therapeutics worth $37.9K as of Q2 2026.
Quadrature Capital sold 17,701 Pliant Therapeutics shares in Q2 2026, an estimated $21.5K.
Pliant Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1522 holding.
Quadrature Capital first reported a position in Pliant Therapeutics in Q1 2025 and has held it in 6 quarters since.
Quadrature Capital's Pliant Therapeutics position peaked at $119K in Q4 2025.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.